Lucid Diligence Brief: Nabla Bio and Takeda, second AI protein-design collaboration
Lucid Diligence Brief: Nabla Bio and Takeda, second AI protein-design…
Lucid Diligence Brief: Tubulis €308m Series C, NaPi2b ADC TUB-040
Lucid Diligence Brief: Tubulis €308m Series C, NaPi2b ADC TUB-040 Professional…
Lucid Diligence Brief: Verily UCHealth AI collaboration
Lucid Diligence Brief: Verily UCHealth AI collaboration Professional audiences…
Lucid Diligence Brief: Kailera Therapeutics $600m Series B
Lucid Diligence Brief: Kailera Therapeutics $600m Series B Professional…
Lucid Diligence Brief: Excellergy ECRIs, $70M investment
Lucid Diligence Brief: Excellergy ECRIs, $70M investment Professional audiences…
Lucid Diligence Brief: Shuttle Pharma x Molecule.ai LOI
Lucid Diligence Brief: Shuttle Pharma x Molecule.ai LOI Professional audiences…
Lucid Diligence Brief: Ascenta Capital Fund I, $325M final close
Lucid Diligence Brief: Ascenta Capital Fund I, $325M final close Professional…
Lucid Diligence Brief: Bristol Myers Squibb's acquisition of Orbital Therapeutics
Lucid Diligence Brief: Bristol Myers Squibb's acquisition of Orbital…
Lucid Diligence Brief: Novo Nordisk to acquire Akero Therapeutics for up to $5.2 billion
Lucid Diligence Brief: Novo Nordisk to acquire Akero Therapeutics for up to…
Lucid Diligence Brief: Salt AI $10M raise
Lucid Diligence Brief: Salt AI $10M raise Professional audiences only. Not…